Inhibikase Therapeutics (IKT)
(Real Time Quote from BATS)
$1.74 USD
-0.15 (-7.94%)
Updated May 22, 2024 10:38 AM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IKT 1.74 -0.15(-7.94%)
Will IKT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for IKT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IKT
Here's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock Now
New Strong Buy Stocks for February 13th
IKT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for February 8th
New Strong Buy Stocks for February 8th
New Strong Buy Stocks for February 6th
Other News for IKT
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Korro Bio (KRRO) and Inhibikase Therapeutics (IKT)
Inhibikase Therapeutics price target lowered by $4 at H.C. Wainwright, here's why
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
Inhibikase Therapeutics prices its direct offering, warrant inducement
Inhibikase announces pricing of registered direct offering, warrant inducement